Opinion|Videos|August 29, 2024
When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- In your experience, how can physicians and caregivers both support patients in navigating a therapy change? Which resources can best help support patients during a treatment transition?
Advertisement
Related to this article
Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.
Azacitidine/venetoclax improving EFS over chemotherapy in fit patients with AML is an “important outcome,” according to Amir T. Fathi, MD.
Poster presentations at SOHO 2026 may inform practice across acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia.
Combination approvals for revumenib and ziftomenib in relapsed/refractory acute myeloid leukemia may arrive before frontline approvals, according to Eunice Wang, MD.
Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?
3
Novel Macrocyclic EGFR TKI Shows Responses in EGFR C797S–Positive NSCLC
4
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
5